Evidence map›Paper›PMID 42265335›Full record

SynthesisBritish journal of cancer2026

Body mass index, adjuvant chemotherapy, toxicity, and survival in non-metastatic colorectal cancer: an individual participant data meta-analysis (OCTOPUS).

Corinna G V Slawinski, Lee Malcomson, Jorge Barriuso, Hui Guo, Richard Emsley, Richard D Riley, Andrea Harkin, Timothy Iveson, Robert Glynne-Jones, Cornelis J H van de Velde and 1 more

Abstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Corinna G V SlawinskiDivision of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK. Slawinski.c@doctors.org.uk.ORCID http://orcid.org/0000-0003-1243-7253
Lee MalcomsonDivision of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.
Jorge BarriusoDivision of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.
Hui GuoCentre for Biostatistics, School of Health Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.
Richard EmsleyDepartment of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Richard D RileyCentre Institute of Applied Health Research, College of Medical Dental Sciences, University of Birmingham, Birmingham, UK.
Andrea HarkinCRUK Glasgow CTU, University of Glasgow, Glasgow, UK.
Timothy IvesonUniversity Hospital Southampton NHS Foundation Trust, Southampton, UK.
Robert Glynne-JonesDepartment of medical oncology, Mount Vernon Cancer Centre for Cancer Treatment, Northwood, UK.ORCID http://orcid.org/0000-0002-6742-222X
Cornelis J H van de VeldeDepartment of surgery, Leiden University Medical Centre, Leiden, The Netherlands.
Andrew G RenehanDivision of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.ORCID http://orcid.org/0000-0002-9115-4405

Funding

Cancer Research UK (CRUK) C147/A18083 and C147/A25254
6 · The paper itself

Abstract

introductionWe aimed to disentangle whether elevated body mass index (BMI) is directly associated with adverse survival in primary colorectal cancer (CRC), or indirectly through treatment-related mechanisms, e.g., dose-capping adjuvant chemotherapy (ACT) and toxicity, using individual participant data meta-analysis (IPD-MA) and causal inference approaches.

methodsUsing BMI from four CRC-ACT randomised trials [OCTOPUS], and two ACT adherence measures (average cumulative relative dose [ACRD]; average relative dose intensity [ARDI]), we performed two-stage random effects IPD-MA, assessing total (TE) and direct effects (DE) (excluding and including mediators, respectively) of pre-defined causal paths, with overall survival (OS) as primary outcome.

findingsIn 7264 patients, the TE of 5 kg/m

conclusionOur study establishes possible adverse indirect effects of obesity on CRC survival, through treatment-selection, supporting full BSA-based ACT dosing.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBody Mass IndexColorectal NeoplasmsAgedChemotherapy, AdjuvantFemaleHumansMaleMiddle AgedRandomized Controlled Trials as Topic

Identifiers

PMID42265335
PMCPMC13478639

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.